Olema Oncology
Developing better medicines for breast cancer and beyond
San Francisco, United States · Founded 2006
- Headquarters
- San Francisco, California
- Employees
- 51–200
- Founded
- 2006
- Business Model
- B2B
About
Olema Oncology is a clinical-stage biopharmaceutical company focused on transforming the treatment paradigm for metastatic breast cancer and endocrine-driven cancers. The company's lead program, palazestrant (OP-1250), is a differentiated oral complete estrogen receptor antagonist (CERAN) in late-stage clinical development; its pipeline also includes OP-3136, a potent oral KAT6 inhibitor. Founded in 2006 and headquartered in San Francisco with operations in Cambridge, Massachusetts, Olema is a publicly traded company (Nasdaq) advancing multiple clinical trials for patients with ER+/HER2- metastatic breast cancer and other solid tumors.
Summary
Olema Oncology is a Biotech company based in San Francisco, United States, founded in 2006.
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biopharmaceutical services company
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Specialty pharmaceutical company
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...